Nexalin Technology (NXL) Share-based Compensation (2021 - 2026)
Nexalin Technology's (NXL) quarterly Share-based Compensation came in at $478611.0 in Q1 2026, down 24.85% year-on-year from $636844.0 in Q1 2025, and down 42.44% quarter-over-quarter from $831529.0 in Q4 2025.
Nexalin Technology (NXL) Share-based Compensation (2021 - 2026) Analysis & Trends
Nexalin Technology's Share-based Compensation history runs 6 years deep, the most recent figure standing at $478611.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 24.85% year-over-year to $478611.0 in Q1 2026; TTM through Mar 2026 was $3.0 million, a 26.54% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, down 12.28% from the prior year.
- Share-based Compensation eased to $478611.0 in Q1 2026 per NXL's latest filing, from $831529.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.6 million in Q4 2024 and bottomed at $88388.0 in Q2 2023.
- The 5-year median for Share-based Compensation is $393447.0 (2024), against an average of $569678.9.
- Across the five-year window, Share-based Compensation tumbled 87.67% in 2022 and soared 471.86% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $184291.0 in 2022, then surged by 47.24% to $271342.0 in 2023, then surged by 471.86% to $1.6 million in 2024, then slumped by 46.41% to $831529.0 in 2025, then tumbled by 42.44% to $478611.0 in 2026.
- Per Business Quant, the three latest NXL Share-based Compensation figures stand at $478611.0 (Q1 2026), $831529.0 (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 35.80 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 35.12 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | 478,611.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 478,611.00 |
| Mar 31, 2026 | 478,611.00 |
| Dec 31, 2025 | 831,529.00 |
| Dec 31, 2025 | 831,529.00 |
| Sep 30, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 572,100.00 |
| Jun 30, 2025 | 572,100.00 |
| Mar 31, 2025 | 636,844.00 |
| Mar 31, 2025 | 636,844.00 |
| Dec 31, 2024 | 1.55 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 308,283.00 |
| Jun 30, 2024 | 308,283.00 |
| Mar 31, 2024 | 161,349.00 |
| Mar 31, 2024 | 161,349.00 |
| Dec 31, 2023 | 271,342.00 |
| Dec 31, 2023 | 271,342.00 |